J&J: study to prevent dengue fever terminated

(CercleFinance.com) - Johnson & Johnson announced today that it has stopped a Phase 2 study of its antiviral candidate mosnodenvir, designed to prevent dengue fever in adults aged 18 to 65.


J&J states that no safety issues have been identified and that this decision is part of a strategic reorientation of its research portfolio in communicable diseases.

Efficacy data will be available once the final analysis has been completed.

Mosnodenvir, already deemed safe and well-tolerated in previous studies, had shown antiviral activity against dengue fever (DENV-3) in a Phase 2a study.


Copyright (c) 2024 CercleFinance.com. All rights reserved.